Evaluation of the safety and immunogenicity of synthetic Aß42 (AN1792) in patients with AD
Neurology Bayer et al.
64: 94
Data Supplement
Three tables and one figure; one Word document and one jpg file.
Files in this Data Supplement:
E1
-
(E)T-1 Overview of adverse events occurring during treatment with AN1792 + QS-21 or QS-21 alone; (E)T-2 Summary of treatment-related adverse events reported by >/= 2 patients during treatment with AN1792 + QS-21 or QS-21 alone; (E)T-3 Effect of AN1792 + QS-21 or QS-21 alone on ADAS-Cog, MMSE, DAD and ADCS-CGIC scores among all patients who received at least one dose of study drug. Observed mean values with SD are presented; Word document.